CureVac raised $245m in an initial public offering on Nasdaq to accelerate the development of its Covid-19 vaccine. The sale priced at the top of the range, at $16 per share, and the stock was around …
( read original story …)
The Shanghai News
CureVac raised $245m in an initial public offering on Nasdaq to accelerate the development of its Covid-19 vaccine. The sale priced at the top of the range, at $16 per share, and the stock was around …
( read original story …)